"The final manuscript will serve as both an update and extension of the 2013 practice guideline that established evidence-based identification and best practices for molecular biomarker testing for patients diagnosed with non-squamous, non-small cell lung cancer of all stages," said Neal I. Lindeman, MD, director of Molecular Diagnostics Laboratory at Brigham and Women's Hospital, associate professor of pathology at Harvard Medical School, and AMP member. "This guideline will continue to be updated as appropriate, and guidelines for other biomarkers associated with lung cancer will be added as more research becomes available."
Together with a multi-disciplinary expert panel, Co-chairs Cagle, Yatabe, and Lindeman formulated new draft recommendations addressing these key questions:
Ad Statistics
Times Displayed: 22687
Times Visited: 478 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
-What other genes, previously not addressed, should be tested in lung adenocarcinoma?
-Is immunohistochemistry reliable for screening for ALK translocations?
-What are the types and rates of secondary resistance in patients who are undergoing treatment with targeted tyrosine kinase inhibitors?
-What are the clinical performance characteristics of circulating DNA/CTC in plasma when used for diagnosis of primary lung adenocarcinoma or relapse?
-Are there biomarkers that are predictive of clinical outcome in squamous and small cell lung carcinomas?
-What key considerations are there regarding next-generation sequencing panels targeting key genes or regions of interest?
In conjunction with revising the guideline, CAP, IASLC, and AMP will develop clinical tools and resources for pathologists and oncologists that summarize the findings and recommendations. The organizations expect to develop a patient guide for further understanding, including questions for patients to ask their physicians.
###
About the College of American Pathologists (CAP):
As the leading organization of 18,000 board-certified pathologists, the CAP serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP's Laboratory Improvement Programs, initiated 65 years ago, currently has customers in more than 100 countries, accrediting 7,800 laboratories and providing proficiency testing to 20,000 laboratories worldwide. Find more information about the CAP at cap.org. Follow the CAP on Twitter at @pathologists.
About the International Association for the Study of Lung Cancer (IASLC):
